Because treatment with<unk>  carries a risk of cytokine release syndrome and neurological toxicities, the FDA has mandated that hospitals be certified for its use prior to treatment of any patients.
Axicabtagene ciloleucel
Efgartigimod alfa
Brigatinib
Turoctocog alfa
Etalocib
Seviteronel
Encorafenib
Tucatinib